News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR) Soars As Cancer Drug Meets Main Goal In Phase 2 Study



12/11/2013 7:22:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CytRx Corp said its experimental cancer drug improved survival rates in soft tissue sarcoma patients without the disease progressing, compared to chemotherapy alone, sending its shares up 75 percent before the bell.

The mid-stage trial tested the drug, aldoxorubicin, against a chemotherapy drug, doxorubicin, in 123 patients.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Market Watch
Read at Street Insider
Read at Wall Street Journal


comments powered by Disqus
   
Sarcoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES